Companies · Other Health Care

electroCore, Inc.

ROCKAWAY · Other Health Care

Diligence memoA one-page analyst read on electroCore, Inc. — recommendation, valuation, rhythm, risks.
$87.3M
Total raised · real
10
Rounds
0.2×
Latest step-up
Top 6%
Sector rank · raised
Series C
Latest stage · inferred · Thu Oct 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

electroCore, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.05× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
Active
  • Last raise 9 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

electroCore, Inc. is one of 5377 Other Health Care companies tracked from ROCKAWAY. By capital raised it ranks among the largest (ahead of 95% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2025-10-02
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BPre-Seed · 2012-11-15 Raised $500K (real) Modeled valuation $15M (est)Pre-Seed2012Seed · 2016-06-29 Raised $1.5M (real) Modeled valuation $37M (est)Seed2016Series B · 2017-08-21 Raised $36M (real) Modeled valuation $798M (est)Series B2017Series B · 2017-08-21 Raised $36M (real) Modeled valuation $798M (est)Series B2017Series C · 2017-08-21 Raised $71M (real) Modeled valuation $1.6B (est)Series C2017Series C · 2020-04-14 Raised $1.7M (real) Modeled valuation $40M (est)Series C2020Series C · 2020-05-14 Raised $1.5M (real) Modeled valuation $35M (est)Series C2020Series C · 2020-05-18 Raised $464K (real) Modeled valuation $11M (est)Series C2020Series C · 2021-09-20 Raised $192K (real) Modeled valuation $3.2M (est)Series C2021Series C · 2023-08-02 Raised $750K (real) Modeled valuation $7.8M (est)Series C2023Series C · 2024-06-05 Raised $7.8M (real) Modeled valuation $65M (est)Series C2024Series C · 2025-10-02 Raised $1.9M (real) Modeled valuation $11M (est)Series C2025Cumulative $159M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2012
Seed$1.5M · 2016
Series B$36.0M · 2017no Series A on file
Series B extension$36.0M · 2017
Series C$70.9M · 2017
Series C extension$1.7M · 2020
Series C extension$1.5M · 2020
Series C extension$464K · 2020
Series C extension$192K · 2021
Series C extension$750K · 2023
Series C extension$7.8M · 2024
Series C extension$1.9M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$11.0M
Base estimate est.
$6.7M
Conservative case
$14.1M
Upside case
$12.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $15.4M · 2012-11-152012Seed · modeled $37.2M · 2016-06-29Series B · modeled $797.6M · 2017-08-21Series B · modeled $797.6M · 2017-08-21Series C · modeled $1.6B · 2017-08-21Series C · modeled $40.0M · 2020-04-14Series C · modeled $35.4M · 2020-05-14Series C · modeled $10.6M · 2020-05-18Series C · modeled $3.2M · 2021-09-20Series C · modeled $7.8M · 2023-08-02Series C · modeled $65.3M · 2024-06-05Series C · modeled $11.0M · 2025-10-022025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
0.8 yr
Elapsed time used
0.8 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$6.8M/yr
Capital velocity
13.6 yr
On record since
2012
First round
12
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 36× above median
This company$87.3M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.9M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$11.0M
Sector median$22.1M

Raised more than 95% of sector peers (real $). Modeled value above 36% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 20.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)RESTOR3D, Inc. · Series C Raised $239.2M · modeled $522.3M (est)ByHeart, Inc. · Series C Raised $378.4M · modeled $493.6M (est)SpyGlassPharma, Inc. · Series C Raised $134.8M · modeled $485.1M (est)VantAI Holdings, Inc. · Series C Raised $86.3M · modeled $475.6M (est)BioIntelliSense, Inc. · Series C Raised $140.0M · modeled $329.0M (est)ObjectiveHealth, Inc. · Series C Raised $68.0M · modeled $321.2M (est)VentureMed Group, Inc. · Series C Raised $59.8M · modeled $288.2M (est)Exo Imaging, Inc. · Series C Raised $169.6M · modeled $284.6M (est)InspireMD, Inc. · Series C Raised $117.2M · modeled $248.3M (est)Fonar, Llc · Series C Raised $51.2M · modeled $229.0M (est)MicroTransponder, Inc. · Series C Raised $117.7M · modeled $223.3M (est)Fourth Edge LLC · Series C Raised $119.7M · modeled $222.0M (est)electroCore, Inc. (this company) Raised $87.3M · modeled $11.0M (est)electroCore, Inc.
CompanyStageRaised · realValue · estvs peer med.
RESTOR3D, Inc.Series C$239.2M$522.3M2.31×
ByHeart, Inc.Series C$378.4M$493.6M2.18×
SpyGlassPharma, Inc.Series C$134.8M$485.1M2.14×
VantAI Holdings, Inc.Series C$86.3M$475.6M2.10×
BioIntelliSense, Inc.Series C$140.0M$329.0M1.45×
ObjectiveHealth, Inc.Series C$68.0M$321.2M1.42×
VentureMed Group, Inc.Series C$59.8M$288.2M1.27×
Exo Imaging, Inc.Series C$169.6M$284.6M1.26×
InspireMD, Inc.Series C$117.2M$248.3M1.10×
Fonar, LlcSeries C$51.2M$229.0M1.01×
MicroTransponder, Inc.Series C$117.7M$223.3M0.99×
Fourth Edge LLCSeries C$119.7M$222.0M0.98×
electroCore, Inc. this companySeries C$87.3M$11.0M0.05×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2012-11-15$2.8M$15.4M85%
Seed$1.5M2016-06-29$7.5M$37.2M85%
Series B$36.0M2017-08-21$200.0M$797.6M90%
Series B$36.0M2017-08-21$200.0M$797.6M90%
Series C$70.9M2017-08-21$472.6M$1.6B90%
Series C$1.7M2020-04-14$11.7M$40.0M90%
Series C$1.5M2020-05-14$10.3M$35.4M90%
Series C$464K2020-05-18$3.1M$10.6M90%
Series C$192K2021-09-20$1.3M$3.2M90%
Series C$750K2023-08-02$5.0M$7.8M90%
Series C$7.8M2024-06-05$52.3M$65.3M90%
Series C$1.9M2025-10-02$12.4M$11.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2012-11-15
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$1.5M2016-06-29
    • Raised again after 43 mo — slower than the ~14 mo sector norm.
    • Round 3.0× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  3. Series B$36.0M2017-08-21
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 24.0× larger than the prior — scaling up.
    • 31 investors on this round.
  4. Series B$36.0M2017-08-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 31 investors on this round.
  5. Series C$70.9M2017-08-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 94 investors on this round.
  6. Series C$1.7M2020-04-14
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 40.5× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  7. Series C$1.5M2020-05-14
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  8. Series C$464K2020-05-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  9. Series C$192K2021-09-20
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
  10. Series C$750K2023-08-02
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 3.9× larger than the prior — scaling up.
    • 6 investors on this round.
  11. Series C$7.8M2024-06-05
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 10.5× larger than the prior — scaling up.
    • 13 investors on this round.
  12. Series C$1.9M2025-10-02
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 4.2× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~14mo cadence
$1.9M
Modeled next size est.range $1.9M$3.0M
0.2×
Last step-up
$6.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Rubin10 other2016-06
James L.L. Tullis5 other2020-04
Brent Saunders4 other2012-11
Trevor Moody4 other2016-06
Jeffrey Vinik3 other2017-08
Daniel S. Goldberger1 other2020-04
John P. Gandolfo1 other2020-04
JP Errico1 other2016-06
Reese Terry1 other2016-06
Trevor J. Moody1 other2020-04
Brian S. Posner2020-04
Charles S. Theofilos2024-06
Elena C. Bonfiglioli2025-10
Francis Amato2012-11
Frank Amato2016-06
Glenn Vraniak2017-08
Gordon Donald2012-11
James C. Theofilos2025-10
James Tullis2017-08
Jim Tullis2016-06
Joseph Errico2012-11
Joseph P. Errico2020-05
Joshua S. Lev2025-10
J.P. Errico2017-08
Registry & provenance

electroCore, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1560258
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alphatec Holdings, Inc.Other Health CareSeries C$133.7M$608.7Mnetwork1 shared operator · same sector · same stage
CurvaFix, Inc.Other Health CareSeries C$50.7M$478.1Mnetwork1 shared operator · same sector · same stage
EBR Systems, Inc.Software / TechSeries C$89.6M$203.3Mnetwork1 shared operator · same stage
AxelaCare Holdings, Inc.Other Health CareSeries C$66.5M$12.0Msame sector · same stage
IDev Technologies IncOther Health CareSeries B$44.2M$18.4Mnetwork1 shared operator · same sector
OJO Holdings Corp.Other TechnologySeries C$80.5M$1.3Bnetwork1 shared operator · same stage
Pivot Medical IncOther Health CareSeries B$43.1M$717.7Mnetwork1 shared operator · same sector
Synageva Biopharma Corp.BiotechnologySeries C$120.8M$512.0Mnetwork1 shared operator · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Stimcore, Inc.Other Health CarePre-Seed$2.6M88%
EmStop Inc.Other Health CareSeed$26.5M83%
CoreMedica Laboratories Inc.Other Health CareSeed$61.1M82%
ElectraDx, Inc.Other Health CareSeries A$80.8M82%
Cardionomic, Inc.Other Health CareSeries B$76.3M82%
Intellihealth, Inc.Other Health CareSeries B$22.6M82%
Spark Biomedical Inc.Other Health CareSeries B$158.8M82%
AmplifiDx, Inc.Other Health CarePre-Seed$6.1M81%
Frequently asked
How much funding has electroCore, Inc. raised?
electroCore, Inc. has raised approximately $87.3M in disclosed capital across 10 recorded financing rounds, aggregated from public filings.
What is electroCore, Inc.'s estimated valuation?
Provath's modeled valuation for electroCore, Inc. is approximately $11.0M (modeled range $6.7M–$14.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is electroCore, Inc. at?
electroCore, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Oct 02.
What does electroCore, Inc. do and where is it based?
electroCore, Inc. operates in the Other Health Care sector, based in ROCKAWAY.
Explore related

See where electroCore, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at electroCore, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.